GLP 1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review ScienceDirect Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Amylin receptor subunit interactions are modulated by agonists and determine signaling Science Signaling An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed., Eloralintide vs #Cagrilintide